Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
1988 |
| gptkbp:ATCCode |
L01AA06
|
| gptkbp:brand |
Ifex
|
| gptkbp:CASNumber |
3778-73-2
|
| gptkbp:chemicalFormula |
C7H15Cl2N2O2P
|
| gptkbp:contraindication |
severe bone marrow suppression
hypersensitivity to ifosfamide |
| gptkbp:developedBy |
Asta-Werke
|
| gptkbp:discoveredIn |
1960s
|
| gptkbp:excretion |
gptkb:kidney
|
| https://www.w3.org/2000/01/rdf-schema#label |
ifosfamide
|
| gptkbp:metabolism |
liver
|
| gptkbp:relatedTo |
gptkb:cyclophosphamide
|
| gptkbp:requiresCoAdministration |
mesna
|
| gptkbp:sideEffect |
nausea
vomiting hair loss neurotoxicity myelosuppression hemorrhagic cystitis |
| gptkbp:usedFor |
gptkb:cancer
gptkb:rhabdomyosarcoma leukemia testicular cancer |
| gptkbp:bfsParent |
gptkb:CYP3A4
|
| gptkbp:bfsLayer |
5
|